Aivita Biomedical Inc. in Irvine said Phase 2 clinical trials on one of its drugs showed positive results in treating glioblastoma brain cancer.
The Irvine developmental drugmaker said a 76% survival rate at 12 and 15 months after treatment with cell immunotherapies bested a control group’s 61% rate at 12 months and 48% at 15 months.
“Treatment and monitoring of patients is ongoing [but] we are very encouraged by these interim results,” Aivita Chief Medical Officer Dr. Robert Dillman said.
The drug in testing is a novel immunotherapy that includes each patient’s own immune cells-dendritic cells infused with tumor antigens specific to the patient’s tumor.
Privately held Aivita has three clinical trials ongoing. Others are testing cell-derived immunotherapies for ovarian cancer and melanoma.